Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Kishimoto M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1f7f497fa7da4fc2b61b44b6f5d1ddd1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1f7f497fa7da4fc2b61b44b6f5d1ddd1
record_format	dspace
spelling	oai:doaj.org-article:1f7f497fa7da4fc2b61b44b6f5d1ddd12021-12-02T02:27:27ZTeneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes1178-7007https://doaj.org/article/1f7f497fa7da4fc2b61b44b6f5d1ddd12013-05-01T00:00:00Zhttp://www.dovepress.com/teneligliptin-a-dpp-4-inhibitor-for-the-treatment-of-type-2-diabetes-a12957https://doaj.org/toc/1178-7007Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control with a minimal risk of hypoglycemia and weight gain. Teneligliptin, a novel DPP-4 inhibitor, exhibits a unique structure characterized by five consecutive rings, which produce a potent and long-lasting effect. Teneligliptin is currently used in cases showing insufficient improvement in glycemic control even after diet control and exercise or a combination of diet control, exercise, and sulfonylurea- or thiazolidine-class drugs. In adults, teneligliptin is orally administered at a dosage of 20 mg once daily, which can be increased up to 40 mg per day. Because the metabolites of this drug are eliminated via renal and hepatic excretion, no dose adjustment is necessary in patients with renal impairment. The safety profile of teneligliptin is similar to those of other available DPP-4 inhibitors. However, caution needs to be exercised when administering teneligliptin to patients who are prone to QT prolongation. One study has reported that the postprandial blood glucose-lowering effects of teneligliptin administered prior to breakfast were sustained throughout the day, and the effects observed after dinner were similar to those observed after breakfast or lunch. Thus, although clinical data for this new drug are limited, this drug shows promise in stabilizing glycemic fluctuations throughout the day and consequently suppressing the progression of diabetic complications. However, continued evaluation in long-term studies and clinical trials is required to evaluate the efficacy and safety of the drug as well as to identify additional indications for its clinical use.Keywords: teneligliptin, DPP-4 inhibitor, diabetesKishimoto MDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 187-195 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Kishimoto M Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
description	Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control with a minimal risk of hypoglycemia and weight gain. Teneligliptin, a novel DPP-4 inhibitor, exhibits a unique structure characterized by five consecutive rings, which produce a potent and long-lasting effect. Teneligliptin is currently used in cases showing insufficient improvement in glycemic control even after diet control and exercise or a combination of diet control, exercise, and sulfonylurea- or thiazolidine-class drugs. In adults, teneligliptin is orally administered at a dosage of 20 mg once daily, which can be increased up to 40 mg per day. Because the metabolites of this drug are eliminated via renal and hepatic excretion, no dose adjustment is necessary in patients with renal impairment. The safety profile of teneligliptin is similar to those of other available DPP-4 inhibitors. However, caution needs to be exercised when administering teneligliptin to patients who are prone to QT prolongation. One study has reported that the postprandial blood glucose-lowering effects of teneligliptin administered prior to breakfast were sustained throughout the day, and the effects observed after dinner were similar to those observed after breakfast or lunch. Thus, although clinical data for this new drug are limited, this drug shows promise in stabilizing glycemic fluctuations throughout the day and consequently suppressing the progression of diabetic complications. However, continued evaluation in long-term studies and clinical trials is required to evaluate the efficacy and safety of the drug as well as to identify additional indications for its clinical use.Keywords: teneligliptin, DPP-4 inhibitor, diabetes
format	article
author	Kishimoto M
author_facet	Kishimoto M
author_sort	Kishimoto M
title	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
title_short	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
title_full	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
title_fullStr	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
title_full_unstemmed	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
title_sort	teneligliptin: a dpp-4 inhibitor for the treatment of type 2 diabetes
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/1f7f497fa7da4fc2b61b44b6f5d1ddd1
work_keys_str_mv	AT kishimotom teneligliptinadpp4inhibitorforthetreatmentoftype2diabetes
_version_	1718402453679898624

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Ejemplares similares